RU98101904A - RECOMBINANT MVA VIRUS AND ITS USE - Google Patents

RECOMBINANT MVA VIRUS AND ITS USE

Info

Publication number
RU98101904A
RU98101904A RU98101904/13A RU98101904A RU98101904A RU 98101904 A RU98101904 A RU 98101904A RU 98101904/13 A RU98101904/13 A RU 98101904/13A RU 98101904 A RU98101904 A RU 98101904A RU 98101904 A RU98101904 A RU 98101904A
Authority
RU
Russia
Prior art keywords
recombinant mva
mva virus
vaccine
virus
virus according
Prior art date
Application number
RU98101904/13A
Other languages
Russian (ru)
Other versions
RU2198217C2 (en
Inventor
Зуттер Герд
Ольманн Марион
Эрфле Фолькер
Original Assignee
ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ filed Critical ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ
Publication of RU98101904A publication Critical patent/RU98101904A/en
Application granted granted Critical
Publication of RU2198217C2 publication Critical patent/RU2198217C2/en

Links

Claims (28)

1. Рекомбинантный вирус MVA, содержащий и способный экспрессировать, по меньшей мере, один чужеродный ген, встроенный в сайт природной делеции в геноме MVA, но исключающий природный сайт делеции III.1. Recombinant MVA virus, containing and capable of expressing at least one foreign gene, integrated into the natural deletion site in the MVA genome, but excluding the natural deletion site III. 2. Рекомбинантный вирус MVA по п. 1, содержащий и способный экспрессировать, по меньшей мере, один чужеродный ген, встроенный в сайт делеции II в геноме MVA. 2. The recombinant MVA virus according to claim 1, comprising and capable of expressing at least one foreign gene inserted into the deletion site II in the MVA genome. 3. Рекомбинантный вирус MVA по пп. 1-2, в котором чужеродный ген кодирует маркер, терапевтический агент или антигенную детерминанту. 3. Recombinant MVA virus according to claims. 1-2, in which the foreign gene encodes a marker, therapeutic agent or antigenic determinant. 4. Рекомбинантный вирус MVA по п. 3, в котором чужеродный ген кодирует антигенную детерминанту патогенного вируса, бактерии, или другого микроорганизма, или паразита, или опухолевой клетки. 4. The recombinant MVA virus of claim 3, wherein the foreign gene encodes an antigenic determinant of a pathogenic virus, bacterium, or other microorganism, or parasite, or tumor cell. 5. Рекомбинантный вирус MVA по п. 4, в котором чужеродный ген кодирует антигенную детерминанту Plasmodium Fal-ciparum, Mycobacteria, вируса герпеса, вируса гриппа, вируса гепатита или вируса иммунодефицита человека. 5. The recombinant MVA virus of claim 4, wherein the foreign gene encodes the antigenic determinant of Plasmodium Falciparum, Mycobacteria, herpes virus, influenza virus, hepatitis virus or human immunodeficiency virus. 6. Рекомбинантный вирус MVA по пп. 4-5, в котором антигенной детерминантой является nef ВИЧ или тирозиназа человека. 6. Recombinant MVA virus according to claims. 4-5, in which the antigenic determinant is HIV nef or human tyrosinase. 7. Рекомбинантный вирус MVA по п. 6, которым является MVA-LAInef или MVA-hTYP (как описано здесь). 7. The recombinant MVA virus according to claim 6, which is MVA-LAInef or MVA-hTYP (as described here). 8. Рекомбинантный вирус MVA по пп. 1-2, в котором чужеродный ген кодирует РНК-полимеразу Т7. 8. Recombinant MVA virus according to claims. 1-2, in which the foreign gene encodes T7 RNA polymerase. 9. Рекомбинантный вирус MVA по п. 8, которым является MVA-T7 роl (как описано здесь). 9. The recombinant MVA virus according to claim 8, which is MVA-T7 rol (as described here). 10. Рекомбинантный вирус MVA по п.п. 1-9, в котором чужеродный ген находится под транскрипционным контролем раннего/позднего промотора Р7.5 вируса коровьей оспы. 10. Recombinant MVA virus according to claims 1-9, in which the foreign gene is under transcriptional control of the early / late promoter of the P7.5 vaccinia virus. 11. Рекомбинантный вирус MVA по пп. 1-10, который, по существу, очищен от вирусов, способных реплицироваться в клетках человека. 11. Recombinant MVA virus according to claims. 1-10, which is essentially purified from viruses that can replicate in human cells. 12. Рекомбинантный вирус MVA по пп. 8 или 9 для транскрипции последовательностей под транскрипционным контролем промотора РНК-полимеразы Т7. 12. Recombinant MVA virus according to claims. 8 or 9 for transcription of sequences under transcriptional control of the T7 RNA polymerase promoter. 13. Эукариотическая клетка, инфицированная рекомбинантным вирусом MVA по любому из пп. 1-11. 13. A eukaryotic cell infected with a recombinant MVA virus according to any one of paragraphs. 1-11. 14. Эукариотическая клетка по п. 13, которая дополнительно содержит один или несколько экспрессионных векторов, несущих один или несколько чужеродных генов под транскрипционным контролем промотора РНК-полимеразы Т7. 14. The eukaryotic cell according to claim 13, which further comprises one or more expression vectors carrying one or more foreign genes under transcriptional control of the T7 RNA polymerase promoter. 15. Эукариотические клетки по п. 14 для продуцирования полипептидов, кодируемых указанными чужеродными генами, включающего:
а) культивирование указанных клеток в подходящих условиях, и
б) выделение полипептидов, кодированных указанными чужеродными генами.15. Eukaryotic cells according to claim 14 for the production of polypeptides encoded by these foreign genes, including:
a) culturing said cells under suitable conditions, and
b) the selection of polypeptides encoded by these foreign genes. 16. Эукариотическая клетка по п. 14, которая дополнительно содержит экспрессионные векторы, несущие вирусные гены и/или вирусную векторную конструкцию, кодирующую геном вирусного вектора, под транскрипционным контролем промотора РНК-полимеразы Т7. 16. The eukaryotic cell according to claim 14, which further comprises expression vectors carrying viral genes and / or a viral vector construct encoding the viral vector genome under transcriptional control of the T7 RNA polymerase promoter. 17. Эукариотические клетки по п. 16 для продуцирования вирусных частиц, включающего:
а) культивирование указанных клеток в подходящих условиях, и
б) выделение вирусных частиц.17. Eukaryotic cells according to claim 16 for the production of viral particles, including:
a) culturing said cells under suitable conditions, and
b) isolation of viral particles. 18. Эукариотическая клетка по п. 14, которая дополнительно содержит:
а) экспрессионный вектор, несущий ретровирусную векторную конструкцию, способную инфицировать клетки-мишени и регулировать в клетках-мишенях экспрессию одного или нескольких чужеродных генов, присутствующих в указанной ретровирусной векторной конструкции, и
б) один или несколько экспрессионных векторов, несущих гены, кодирующие полипептиды, необходимые для генома указанной ретровирусной векторной конструкции, упаковываемой под транскрипционным контролем промотора РНК-полимеразы Т7.18. A eukaryotic cell according to claim 14, which further comprises:
a) an expression vector carrying a retroviral vector construct capable of infecting target cells and regulating the expression of one or more foreign genes present in said retroviral vector construct in target cells, and
b) one or more expression vectors carrying genes encoding the polypeptides necessary for the genome of the indicated retroviral vector construct, packaged under transcriptional control of the T7 RNA polymerase promoter. 19. Эукариотические клетки по п. 18 для продуцирования ретровирусных частиц, включающего:
а) культивирование указанных клеток в подходящих условиях, и
б) выделение ретровирусных частиц.19. Eukaryotic cells according to claim 18 for the production of retroviral particles, including:
a) culturing said cells under suitable conditions, and
b) isolation of retroviral particles. 20. Рекомбинантный вирус MVA по любому из предыдущих пп. 1-11 для получения вакцины. 20. Recombinant MVA virus according to any one of the preceding paragraphs. 1-11 for receiving the vaccine. 21. Вакцина, содержащая рекомбинантный вирус MVA по пп. 1-11 в физиологически приемлемом носителе. 21. A vaccine containing a recombinant MVA virus according to claims. 1-11 in a physiologically acceptable carrier. 22. Рекомбинантный вирус MVA по любому из предыдущих пп. 1-11 и/или вакцина по п. 21 для иммунизации животного, в том числе человека, включающей инокуляцию указанного животного, в том числе человека, вакциной и/или рекомбинантным вирусом MVA. 22. Recombinant MVA virus according to any one of the preceding paragraphs. 1-11 and / or the vaccine according to claim 21 for immunizing an animal, including a human, comprising inoculating said animal, including a human, with a vaccine and / or recombinant MVA virus. 23. Вакцина по п. 21, содержащая MVA-LAInef (как описано здесь) для предупреждения или лечения ВИЧ-инфекции или СПИДа. 23. The vaccine according to claim 21, containing MVA-LAInef (as described here) for the prevention or treatment of HIV infection or AIDS. 24. Вакцина по п. 21, содержащая MVA-hTYR (как описано здесь) для предупреждения или лечения меланом. 24. The vaccine according to claim 21, containing MVA-hTYR (as described here) for the prevention or treatment of melanoma. 25. Вакцина, включающая в качестве первого компонента рекомбинантный вирус MVA по пп. 8-9 в физиологически приемлемом носителе и в качестве второго компонента ДНК-последовательность, кодирующую антигенную детерминанту, под транскрипционным контролем промотора РНК-полимеразы Т7 в физиологически приемлемом носителе, причем оба указанных компонента присутствуют вместе или отдельно. 25. A vaccine comprising, as a first component, a recombinant MVA virus according to claims. 8-9 in a physiologically acceptable carrier and as a second component, the DNA sequence encoding an antigenic determinant is under transcriptional control of the T7 RNA polymerase promoter in a physiologically acceptable carrier, both of which are present together or separately. 26. Вакцина по п. 25 для иммунизации животного, в том числе человека, включающей инокуляцию указанного животного, в том числе человека, первым и вторым компонентами вакцины либо одновременно, либо с задержкой, но с использованием одного и того же места инокуляции. 26. The vaccine according to claim 25 for immunization of an animal, including humans, including inoculation of the specified animal, including humans, with the first and second components of the vaccine, either simultaneously or with a delay, but using the same inoculation site. 27. Рекомбинантный вирус MVA по п. п. 8 или 9 для получения вакцины по п. 25. 27. Recombinant MVA virus according to claim 8 or 9 to obtain a vaccine according to claim 25. 28. Способ иммунизации животного, в том числе человека, включающий инокуляцию указанного животного вакциной по пп. 21-25, причем компоненты вакцины, по п. 25 вводятся одновременно или с задержкой, но с использованием одного и того же места инокуляции. 28. A method of immunizing an animal, including humans, comprising inoculating said animal with a vaccine according to claims 21-25, and the components of the vaccine, according to claim 25, are administered simultaneously or with a delay, but using the same inoculation site.
RU98101904/13A 1995-07-04 1996-07-03 Recombinant modified smallpox virus, its usage (versions) and cell line infected by virus (versions) RU2198217C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0782/95 1995-07-04
DK78295 1995-07-04

Publications (2)

Publication Number Publication Date
RU98101904A true RU98101904A (en) 2000-01-27
RU2198217C2 RU2198217C2 (en) 2003-02-10

Family

ID=8097499

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101904/13A RU2198217C2 (en) 1995-07-04 1996-07-03 Recombinant modified smallpox virus, its usage (versions) and cell line infected by virus (versions)

Country Status (27)

Country Link
US (6) US6440422B1 (en)
EP (3) EP0836648B1 (en)
JP (3) JP4312260B2 (en)
KR (1) KR19990028617A (en)
CN (3) CN1782071A (en)
AT (3) ATE304057T1 (en)
AU (1) AU721735B2 (en)
BR (1) BR9609303B8 (en)
CA (3) CA2225278C (en)
CZ (1) CZ292460B6 (en)
DE (3) DE69635172T2 (en)
DK (3) DK0836648T3 (en)
EE (3) EE05138B1 (en)
ES (3) ES2249647T3 (en)
HK (2) HK1009830A1 (en)
HU (2) HU229261B1 (en)
IL (5) IL122120A (en)
MX (1) MX9800025A (en)
NO (1) NO322476B1 (en)
NZ (1) NZ313597A (en)
PL (1) PL186857B1 (en)
PT (1) PT836648E (en)
RU (1) RU2198217C2 (en)
SI (3) SI0836648T1 (en)
TW (2) TW575664B (en)
UA (3) UA68327C2 (en)
WO (1) WO1997002355A1 (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
MY119381A (en) * 1996-12-24 2005-05-31 Gsf Forschungszentrum Umwelt Recombinant mva virus, and the use thereof
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (en) * 1998-10-22 2000-04-28 Transgene Sa Biological material for preparation of pharmaceuticals useful e.g. as anticancer or antiviral agents, comprises a nucleic acid expressing an antibody that activates immune cells
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
US20150231227A1 (en) * 2000-03-02 2015-08-20 Emory University Compositions and methods for generating an immune response
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
DE10042598A1 (en) * 2000-08-30 2002-03-28 Gsf Forschungszentrum Umwelt Recombinant MVA with the ability to express the HER-2 / Neu gene
WO2002031168A2 (en) * 2000-10-10 2002-04-18 Genstar Therapeutics Minimal adenoviral vector and recombinant vaccines based thereon
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7740863B2 (en) 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
DE10143490C2 (en) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Recombinant MVA with the ability to express HCV structural antigens
DE10144664B4 (en) * 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccinia virus MVA-E3L knockout mutants and use thereof
CA2466413C (en) 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
NZ533586A (en) * 2001-12-20 2005-02-25 Bavarian Nordic As Method for the recovery and purification of poxviruses from infected cells using high pressure homogenisation
EP1839672A3 (en) * 2002-04-19 2007-11-21 Bavarian Nordic A/S Modified vaccinia virus Ankara for the vaccination of neonates
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA007811B1 (en) 2002-05-16 2007-02-27 Бавариан Нордик А/С Intergenic regions as insertion sites in the genome of modified vaccine virus ankara (mva)
EA009525B1 (en) * 2002-05-16 2008-02-28 Бавариан Нордик А/С Recombinant modified vaccinia virus ankara comprising the cowpox ati promoter and methods of use virus and promoter
KR101044538B1 (en) 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DE10249390A1 (en) * 2002-10-23 2004-05-13 Ruprecht-Karls-Universität Heidelberg Recombinant MVA strains as potential vaccines against P. falciparum malaria
PT1567653E (en) 2002-11-25 2007-10-01 Bavarian Nordic As Recombinant poxvirus comprising at least two cowpox ati promoters
ATE403005T1 (en) * 2003-02-18 2008-08-15 Helmholtz Zentrum Muenchen RECOMBINANT MVA AND METHOD FOR PRODUCING SAME
JP5052893B2 (en) 2003-02-20 2012-10-17 アメリカ合衆国 New insertion site in the pox vector
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
MXPA05010260A (en) 2003-03-27 2006-03-17 Ottawa Health Research Inst Mutant vesicular stomatitis viruses and use thereof.
WO2004093905A1 (en) * 2003-04-16 2004-11-04 City Of Hope Human cytomegalovirus antigens expressed in mva and methods of use
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
ES2359473T3 (en) 2003-07-21 2011-05-23 Transgene S.A. MULTIFUNCTIONAL CYTOKINS.
WO2005017208A1 (en) * 2003-07-31 2005-02-24 George Mason Intellectual Properties, Inc. Compositions and methods for treating or preventing hiv infection
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
DK1536015T3 (en) * 2003-11-24 2008-02-18 Bavarian Nordic As Promoters for expression in modified vaccinia virus Ankara
JP4719855B2 (en) 2003-12-05 2011-07-06 国立大学法人北海道大学 Highly safe pressure ulcer vaccine virus and vaccinia virus vector
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
US20090060947A1 (en) * 2006-05-19 2009-03-05 Sanofi Pasteur, Inc. Immunological compositions
DK2029756T3 (en) * 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
WO2008076157A2 (en) * 2006-09-08 2008-06-26 Duke University Modified vaccinia ankara virus vaccine
CN102026645B (en) 2006-09-15 2016-01-27 渥太华医院研究机构 Oncolytic rhabdovirus
CA2665068C (en) 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
US20080241139A1 (en) * 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
CA2676129A1 (en) * 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
EP2152736B1 (en) 2007-05-03 2017-07-05 Lysomab GmbH Complement factor h-derived short consensus repeat-antibody constructs
US8003364B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
JP2010526546A (en) * 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ Purification of vaccinia virus and recombinant vaccinia virus vaccines
US8003363B2 (en) 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US20100285050A1 (en) * 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
BRPI0800485B8 (en) * 2008-01-17 2021-05-25 Univ Minas Gerais recombinant viral vectors, leishmaniasis vaccine composition and leishmaniasis vaccination method
CN102257134B (en) 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 Methods using ion exchange and gel filtration chromatography for poxvirus purification
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
KR20120052352A (en) * 2009-08-07 2012-05-23 트랜스진 에스.에이. Composition for treating hbv infection
EP2501405A4 (en) * 2009-11-20 2013-12-04 Inviragen Inc Compositions, methods and uses for poxvirus elements in vaccine constructs
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
EP2668201A2 (en) 2011-01-28 2013-12-04 Sanofi Pasteur SA Immunological compositions comprising hiv gp41 polypeptide derivatives
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
PL2691530T3 (en) 2011-06-10 2019-02-28 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PL2739293T3 (en) * 2011-08-05 2020-11-16 Sillajen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2761011B1 (en) * 2011-09-26 2018-05-23 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
KR20150058152A (en) 2012-07-10 2015-05-28 트랜스진 에스아이 Mycobacterial antigen vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
EP2912069B1 (en) 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (en) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV vaccines
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en) * 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
RS61902B1 (en) 2014-09-26 2021-06-30 Beth Israel Deaconess Medical Ct Inc Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2016369326B2 (en) 2015-12-15 2019-02-21 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (en) 2016-02-03 2018-12-26 Geovax Inc compositions and methods for generating an immune response to a flavivirus
MX2018010231A (en) * 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors.
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US10273268B2 (en) 2016-06-16 2019-04-30 Janssen Vaccines & Prevention B.V. HIV vaccine formulation
AU2017318689A1 (en) 2016-09-02 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
HUE052008T2 (en) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
MA49397A (en) 2017-06-15 2020-04-22 Bavarian Nordic As POXVIRUS VECTORS CODING FOR HIV ANTIGENS, AND METHODS FOR USING THEM
EP3641803A2 (en) 2017-06-21 2020-04-29 Transgene Personalized vaccine
BR112020000867A2 (en) 2017-07-19 2020-07-21 Janssen Vaccines & Prevention B.V. hiv envelope protein mutations stabilizing the trimer
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
WO2019055888A1 (en) 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP7320601B2 (en) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 Broad-spectrum anti-influenza vaccine immunogen and its use
TW202110476A (en) 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
KR20220082033A (en) * 2019-10-16 2022-06-16 칼리버 임뮤노쎄라퓨틱스, 인크. Producer Virus for In Situ Generation of Retroviruses
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
IL308018A (en) 2021-04-30 2023-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4108257A1 (en) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023220283A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (en) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Mva-based vectors and their use as vaccine against sars-cov-2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (en) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa ANTIVARIOLIC VACCINE
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
US5679511A (en) * 1986-10-06 1997-10-21 Donald Guthrie Foundation For Medical Research, Inc. CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
CN1042564A (en) * 1988-11-11 1990-05-30 中国科学院上海生物化学研究所 The preparation method of Hepatitis B virus vaccine and goods thereof
JPH03271233A (en) * 1990-03-19 1991-12-03 Inst Pasteur Inducement of protective action against virus infection by synergism between peptides cor- responding to virus envelope glycoprotein and neutral epitope of its glycoprotein
EP0613378A1 (en) * 1991-10-28 1994-09-07 Institut Pasteur Induction of protection against viral infection by synergy between viral proteins and viral peptides
ES2172287T4 (en) * 1992-12-22 2003-04-16 Ludwig Inst Cancer Res METHODS OF DETECTION AND TREATMENT OF INDIVIDUALS WITH ABNORMAL CELLS THAT EXPRESS THE PEPTIDIC ANTIGENS HLA-A2 / TIROSINASA.
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
CA2173138A1 (en) * 1993-10-19 1995-04-27 Masafumi Takiguchi Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

Similar Documents

Publication Publication Date Title
RU98101904A (en) RECOMBINANT MVA VIRUS AND ITS USE
CA2596274A1 (en) Recombinant mva virus, and the use thereof
US7993651B2 (en) Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Paliard et al. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
Gherardi et al. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide
CA2481521A1 (en) Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
RU2003118436A (en) ANKARA MODIFIED VERSION OF ANKARA
EA002020B1 (en) Method in generating an antiviral immune response in a human or an animal
CN101142319B (en) Vaccines based on the use of mv
RU2003128991A (en) RECOMBINANT POXVIRUS CODING HIMERA IMMUNODEFICIENCY VIRUS CHEMICAL PROTEINS
WO1999013896A1 (en) Attenuated vif dna immunization cassettes for genetic vaccines
WO2004074493A1 (en) Recombinant mva and method for generation thereof
US20150359877A1 (en) Viral Vaccine Vectors
Vanniasinkam et al. Adenoviral gene delivery for HIV-1 vaccination
US20100034851A1 (en) AIDS Vaccine Based on Replicative Vaccinia Virus Vector
AU604791B2 (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
Armand et al. Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice
WO1999015692A2 (en) Dengue virus antigens and treatment of dengue fever
Chugh et al. Induction of broad-based immune response against HIV-1 subtype C gag DNA vaccine in mice
RU2194075C2 (en) Recombinant plasmid dna ptbi-hbsag comprising chimeric gene tbi-hbsag under control of smallpox vaccine promoter p7,5k and strain of recombinant smallpox vaccine inducing immune response against hiv and human hepatitis b in animal body
RU2335540C1 (en) EXPRESSION PLASMID DNA pBMC - nef (A)-hum
RU2345138C2 (en) EXPRESSIVE PLASMID DNA p-BMC-gag (A)-HUM FOR EXPRESSION OF PROTEIN p55 HJV-1 IN EUKARYOTE CELLS
US20040265324A1 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines